Tivozanib Improves PFS in Highly Refractory RCC
The VEGF inhibitor tivozanib (Fotivda) reduced the risk of disease progression or death by 26% compared with sorafenib (Nexavar) in patients with highly refractory advanced or metastatic renal cell carcinoma (RCC), according to topline findings from the phase III TIVO-3 trial.11/07/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology